β-cyclodextrin modification by cross-linking polymerization as highly porous nanomatrices for olanzapine solubility improvement; synthesis, characterization and bio-compatibility evaluation
03 medical and health sciences
0302 clinical medicine
02 engineering and technology
0210 nano-technology
DOI:
10.1016/j.jddst.2021.102952
Publication Date:
2021-11-08T16:45:18Z
AUTHORS (5)
ABSTRACT
Abstract Herein, we report highly porous and amorphous nanomatrices developed by cross-linking polymerization with subsequent condensation technique for solubility, dissolution and ultimately bioavailability enhancement of poorly soluble drug olanzapine (OLN). β-cyclodextrin was chemically cross-linked with monomer 2-acrylamido 2-methylpropane sulfonic acid (AMPS) by using methylene bis acrylamide (MBA) as cross-linking agent. Developed nanomatrices were characterized by zetasizer, FTIR, XRD, SEM, DSC, swelling, sol-gel, drug loading, stability, porosity (%), solubility, and in-vitro dissolution analysis. The developed porous nanomatrices are intended for oral administration of poorly soluble drugs therefore, to determine the biocompatibility of the system to the biological environment, in-vivo cytotoxicity study was also conducted using rabbit model which endorsed the safety of the nanomatrices with biological system. The particle size of nanomatrices were found 152.30 ± 07.46 d.nm. XRD analysis depicted the highly amorphous nature of nanomatrices while. To evaluate the pharmacokinetic profile of olanzapine, in-vivo studies were also conducted. The in-vivo and dissolution experiments revealed that drug release characteristics were significantly improved by nanomatrices as compared with the reference product (OLANZIA®). The solubility of olanzapine by the developed nanomatrices was enhanced noticeably up to 40.11 times which is higher than previously reported β-cyclodextrin formulations. The efficient method of preparation, improved solubility, rapid and high dissolution and non-toxic βCD-co-poly (AMPS) nanomatrices may be a promising approach for oral delivery of poorly soluble drugs.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (94)
CITATIONS (27)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....